Literature DB >> 17334801

Recommendations for the reporting of pleural mesothelioma.

Kelly J Butnor1, Thomas A Sporn, Nelson G Ordonez.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17334801     DOI： 10.1007/s00428-006-0301-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  9 in total

1.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Authors:  V W Rusch; E S Venkatraman
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

2.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

3.  TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.

Authors:  C Di Loreto; F Puglisi; V Di Lauro; G Damante; C A Beltrami
Journal:  Cancer Lett       Date:  1998-02-13       Impact factor: 8.679

4.  Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.

Authors:  P M Cury; D N Butcher; C Fisher; B Corrin; A G Nicholson
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

Review 5.  Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.

Authors:  N G Ordóñez
Journal:  Am J Clin Pathol       Date:  1998-01       Impact factor: 2.493

6.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.

Authors:  Albert Y Chu; Leslie A Litzky; Theresa L Pasha; Geza Acs; Paul J Zhang
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

7.  Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.

Authors:  D J Sugarbaker; J P Garcia; W G Richards; D H Harpole; E Healy-Baldini; M M DeCamp; S J Mentzer; M J Liptay; G M Strauss; S J Swanson
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

9.  Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.

Authors:  N G Ordóñez
Journal:  Am J Surg Pathol       Date:  1998-10       Impact factor: 6.394
  9 in total
  1 in total

1.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.